Colorectal Cancer

An expert from the Duke University School of Medicine describes how the FDA approval of tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer will improve access to treatment.

The FDA based its accelerated approval of tucatinib and trastuzumab combination therapy for HER2-positive metastatic colorectal cancer on results from the phase 2 MOUNTAINEER trial.

An expert from Natera discusses ctDNA’s predictive and prognostic value in resectable colorectal cancer based on data from the GALAXY cohort of the CIRCULATE-JAPAN platform study.

An expert from Natera describes where future research needs to be focused for circulating tumor DNA testing in patients with colorectal cancer following the CIRCULATE-Japan study.

An expert from Natera shares multidisciplinary takeaways from the GALAXY cohort of the CIRCULATE-Japan study, assessing circulating tumor DNA as a prognostic biomarker for resectable colorectal cancer.

An expert from Natera indicates that post-operative ctDNA level may have strong prognostic and predictive value in patients with resectable colorectal cancer.

The panel closes by highlighting currently unmet needs in the treatment and management of metastatic colorectal cancer.

A stool-based, non-invasive, at-home colorectal cancer and advanced adenoma test showed a strong ability to detect disease, according to updated trial results.

Elle Charnisky, a patient with HER2+ metastatic colorectal cancer, and Deanne Griffie, a nurse practitioner, share advice for patients and caregivers living with HER2+ mCRC.

Deanna Griffie, MSN, AGNP-BC, and Tanios Bekaii-Saab, MD, explain how they manage the toxicities of tucatinib in patients with HER2+ mCRC, and how they educate patients on what to expect.

Closing out their review of the metastatic colorectal cancer treatment paradigm, expert panelists consider how the treatment armamentarium will continue to evolve.

Focused discussion on the FRESCO-2 trial, which analyzed use of fruquitinib in the refractory setting of metastatic colorectal cancer.

Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.

Centering discussion on KRASG12C-mutated metastatic colorectal cancer, panelists highlight recent clinical studies of targeted agents in this subset of disease.

The FDA granted breakthrough therapy designation to adagrasib plus cetuximab for patients with KRAS G12C–mutated advanced colorectal cancer based on findings from the phase 1b cohort of the KRYSTAL-1 trial.

Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.

The findings, according to a third-party expert, suggest there’s no benefit to the use of trifluridine and tipiracil alone in earlier lines of therapy for the treatment of colon cancer.

John Strickler, MD, details the design and outcomes of the MOUNTAINEER trial investigating the combination treatment of tucatinib with trastuzumab for HER2+ metastatic colorectal cancer.

A panel of expert oncologists discusses advances in the treatment of BRAFV600E metastatic colorectal cancer and also reviews novel targets being investigated in the setting of metastatic colorectal cancer.

Experts offer insights on the appropriate treatment for patients with HER2-positive metastatic colorectal cancer.

Deanna Griffie, MSN, AGNP-BC, shares how common toxicities in patients with HER2+ mCRC being treated with trastuzumab deruxtecan are treated at her clinic.

The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.

Dr Tanios Bekaii-Saab describes for which patient groups he would use anti-HER2 therapies as a second-line treatment for HER2+ metastatic colorectal cancer.

Expert panelists review data from the MOUNTAINEER study, which tested tucatinib alone or in combination with trastuzumab in patients with metastatic colorectal cancer.

Patient Elle Charnisky shares her experience with a conventional chemotherapy treatment for her HER2+ metastatic colorectal cancer before transitioning to targeted therapies.

Shared perspective on the use of trastuzumab deruxtecan in HER2+ metastatic colorectal cancer following results from the DESTINY-CRC01 trial.

Dr Bekaii-Saab provides an overview of the first-line treatment options in metastatic colorectal cancer, and the factors that impact treatment decision-making.

Tanios Bekaii-Saab, MD, explains the barriers to molecular testing for patients with metastatic colorectal cancer, and how they can be addressed.

A panel of expert oncologists consider how HER2 expression can positively impact the selection of targeted therapies for patients with metastatic colorectal cancer.

Expert perspectives on the PARADIGM study, which highlighted the role of panitumumab in combination with frontline chemotherapy in patients with left-sided, RAS wild-type metastatic colorectal cancer.